Similar Articles

  • Hypertensive chronic kidney disease in African Americans: Strategies for improving care

    David Martins, MD, MS, Lawrence Agodoa, MD and Keith C. Norris, MD, FACP, FASN
    • Cleveland Clinic Journal of Medicine October 2012, 79 (10) 726-734;
    • DOI: https://doi.org/10.3949/ccjm.79a.11109

    • Factors responsible for its rapid progression in African Americans are detectable by screening and modifiable with prompt therapy.

  • TOC Icon

    Chronic kidney disease in African Americans: Puzzle pieces are falling into place

    Joseph V. Nally Jr, MD
    • Cleveland Clinic Journal of Medicine November 2017, 84 (11) 855-862;
    • DOI: https://doi.org/10.3949/ccjm.84gr.17007

    • African Americans are disproportionately affected; genetic variants in APOL1 provide an important explanation.

  • Gout and African Americans: Reducing disparities

    Bharat Kumar, MD and Petar Lenert, MD, PhD
    • Cleveland Clinic Journal of Medicine September 2016, 83 (9) 665-673;
    • DOI: https://doi.org/10.3949/ccjm.83a.15133

    • African Americans are more likely to suffer from gout and are less likely to receive optimal treatment for it.

  • Coronary heart disease in African Americans: primary and secondary prevention

    Luther T. Clark, MD and Obinnaya Emerole, MD
    • Cleveland Clinic Journal of Medicine September 1995, 62 (5) 285-292;

    • How physicians can help improve the cardiovascular health of their black patients, who have a high level of CHD risk factors.

  • Overcoming barriers to hypertension control in African Americans

    Taiye Odedosu, MD, Antoinette Schoenthaler, EdD, Dorice L. Vieira, MLS, MPH, MA, Charles Agyemang, PhD and Gbenga Ogedegbe, MD
    • Cleveland Clinic Journal of Medicine January 2012, 79 (1) 46-56;
    • DOI: https://doi.org/10.3949/ccjm.79a.11068

  • Polycystic kidney disease: Molecular understanding dictating management

    Brian F. Mandell, MD, PhD
    • Cleveland Clinic Journal of Medicine September 2014, 81 (9) 516;
    • DOI: https://doi.org/10.3949/ccjm.81b.09014

    • It was the early 1980s, I was a resident in the emergency room, and the patient had fever, flank pain, hypotension, and a normal urinalysis.

  • Interpreting the African American Heart Failure Trial(A-HEFT)

    Monica Colvin-Adams, MD and Anne L. Taylor, MD
    • Cleveland Clinic Journal of Medicine March 2007, 74 (3) 227-234;

    • This placebo-controlled trial was the first to evaluate a therapy in a specific racial group, and it points the way to a more individualized approach to heart failure therapy.

  • Heart failure in African Americans: Disparities can be overcome

    Alok Sharma, MD, Monica Colvin-Adams, MD, MS and Clyde W. Yancy, MD, MSc
    • Cleveland Clinic Journal of Medicine May 2014, 81 (5) 301-311;
    • DOI: https://doi.org/10.3949/ccjm.81a.13045

    • African Americans are disproportionately affected by heart failure, but discrepant outcomes can be minimized.

  • Gout and chronic kidney disease (December 2010)

    David L. Keller, MD
    • Cleveland Clinic Journal of Medicine February 2011, 78 (2) 81;
    • DOI: https://doi.org/10.3949/ccjm.78c.02001

    • A reader comments on the use of monoamine oxidase inhibitors to treat depression (December 2010) and on the treatment of gout in patients with chronic kidney disease (December 2010).

  • Corneal opacities in a man with chronic kidney disease

    Omer Ibrahim, MD, Linda Amah, MD and Sharon E. Mace, MD, FACEP, FAAP
    • Cleveland Clinic Journal of Medicine June 2015, 82 (6) 339-340;
    • DOI: https://doi.org/10.3949/ccjm.82a.14080

    • Effects of lecithin-cholesterol acyltransferase deficiency include coronary artery disease, renal disease, and corneal opacity.

Previous
Next